Bayer/GSK vardenafil "approvable"
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
FDA deems Bayer/GlaxoSmithKline's erectile dysfunction drug vardenafil "approvable" July 23, requesting additional short-term clinical pharmacology studies for the phosphodiesterase-5 inhibitor. The approvable decision, coming 10 months after the Sept. 25, 2001 NDA submission, pushes back the projected launch date from second-half 2002 to 2003. The launch of Lilly/ICOS' competing ED therapy, Cialis (tadalafil), also has been delayed - to the second half of 2003. FDA similarly requested pharmacology studies from Lilly/ICOS in an April 29 "approvable" letter (Pharmaceutical Approvals Monthly, May 2002, In Brief
You may also be interested in...
Lilly ICOS Cialis complete response
Lilly ICOS submits a complete response to FDA's April 2002 "approvable" letter for Cialis (tadalafil), the firm announces July 1. The second quarter 2003 submission extends the action date to the fourth quarter of 2003 and contains "clinical pharmacology and other data" requested by FDA. The agency also requested pharmacology studies for Bayer's competing erectile dysfunction therapy, Levitra (vardenafil), which became approvable in July 2002 (1Pharmaceutical Approvals Monthly Aug. 1, 2002, In Brief)...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.